Home
Search
Search Results
Previously Searched
3102 results found
Expand All
Apply All
3102 results found

BIO’s Jim Greenwood Meets with India’s PM Modi
Press Release  •  January 13, 2017
Delivers Message: India Must Protects Innovators’ Work Product
Read More

BIO Statement on Proposed Maryland Drug Pricing Legislation
Press Release  •  January 10, 2017
BIO's statement  regarding proposed drug pricing legislation within the Maryland Senate.
Read More

BIO submits comments to Merit-Based Incentive Payment System (MIPS) and Alternative Payment Model (APM) Incentive under the Physician Fee Schedule, and Criteria for Physician-Focused Payment Models
Letters, Testimony & Comments  •  December 23, 2016
The Biotechnology Innovation Organization appreciates the opportunity to offer comments to the final rule Medicare Program; Merit-Based Incentive Payment System (MIPS) and Alternative Payment Model (APM) Incentive under the Physician Fee Schedule, and Criteria for Physician-Focused Payment Models.
Read More

BIO Comments on the National Quality Forum Health and Wellbeing 2015-2017 Report
Letters, Testimony & Comments  •  December 23, 2016
BIO appreciates the opportunity to comment on the National Quality Forum (NQF) Health and Wellbeing 2015-2017 report.
Read More

BIO Submits Comments on FDA Draft Guidance: Coordinated Development of Antimicrobial Drugs and Antimicrobial Susceptibility Test Devices
Letters, Testimony & Comments  •  December 23, 2016
Re: Docket No. FDA-2016-N-0001: The Biotechnology Innovation Organization (BIO) is pleased to submit the following comments on the Food and Drug Administration (FDA) Draft Guidance entitled, “Coordinated Development of Antimicrobial Drugs and Antimicrobial Susceptibility Test (AST) devices” 
Read More

BIO CEO & Investor Conference Programming Announced
Business Development, BIO One-on-One Partnering  •  Press Release  •  December 15, 2016
BIO announced programming for the 19th annual BIO CEO & Investor Conference. Held February 13-14 at the Waldorf Astoria in New York, the annual conference provides an environment for investors, analysts, industry executives and others to discover trends in life sciences, network with peers and potential partners and explore investment opportunities. Established and emerging publicly traded and select private biotech companies are the focus of the event.
Read More

BIO Urges the Senate to Pass the 21st Century Cures Act
Letters, Testimony & Comments  •  December 7, 2016
On behalf of the Biotechnology Innovation Organization (BIO), I am writing to offer our strong support H.R. 34, the 21st Century Cures Act, and urge the Senate to pass this important legislation.
Read More

BIO Applauds Senate Passage of the 21st Century Cures Act
Press Release  •  December 7, 2016
Washington, DC (December 7, 2016) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement today regarding passage of the 21st Century Cures Act by the U.S. Senate:
Read More

New York U.S. Congressional Delegation Sends Letter to PTO Head Michelle Lee
Letters, Testimony & Comments  •  December 7, 2016
Ten members the U.S. House of Representatives from New York wrote to U.S. Patent and Trademark Office Director Michelle K. Lee to express concern with continued abuse of the inter partes review (IPR) system by financial speculators and other third parties with no legitimate interests in the patented technology
Read More

BIO Applauds House Passage of the 21st Century Cures Act
Press Release  •  December 1, 2016
Washington, DC (November 30, 2016) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement today regarding passage of the 21st Century Cures Act by the U.S. House of Representatives:
Read More